CTI BioPharma Corp chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.31
Dividend & YieldN/A$ (N/A)
Beta 0.79
Market capitalization 733.45M
Operating cash flow -95.7M
ESG Scores unknown

Company description

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -489k -7.03M -4.7M 5.58M
Total Cashflows From Investing Activities -30.49M 28.13M -9.62M 12M
Net Borrowings -444k -5.33M -5.33M 43.67M
Total Cash From Financing Activities 63.49M -5.61M 61.07M 97.94M
Change To Operating Activities -163k 1.12M 2.27M 2.28M
Issuance Of Stock 64.22M 1k 67.51M 59.47M
Net Income -29.32M -40.02M -52.45M -97.91M
Change In Cash -6.78M -5.29M 9.25M 25.05M
Effect Of Exchange Rate 44k 2k
Total Cash From Operating Activities -39.82M -27.82M -42.2M -84.89M
Depreciation 593k 546k 532k 526k
Change To Account Receivables -12.39M 13.67M
Other Cashflows From Financing Activities -268k -275k -1.1M -5.2M
Change To Netincome 1.42M 3.89M 12.14M 4.63M
Capital Expenditures -33k -17k -17k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 36.47M 24.11M 25.94M 39.14M
Income Before Tax -29.35M -40.02M -52.45M -97.91M
Net Income -29.32M -40.02M -52.45M -97.91M
Selling General Administrative 22.06M 19.16M 17.63M 56.2M
Gross Profit 26.29M 3.35M
Ebit -32.24M -39.92M -43.57M -95.33M
Operating Income -32.24M -39.92M -43.57M -95.33M
Interest Expense -1.73M -1.52M -1.03M -2.45M
Income Tax Expense
Total Revenue 26.29M 3.35M
Cost Of Revenue 879k
Total Other Income ExpenseNet 2.89M -106k -8.88M -2.58M
Net Income From Continuing Ops -29.35M -40.02M -52.45M -97.91M
Net Income Applicable To Common Shares -29.4M -40.02M -52.45M -97.91M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 36.89M 28.35M 18.21M 68.67M
Total Stockholder Equity 58.69M 23.69M 40.03M 3.77M
Other Current Liabilities 1.55M 2.07M 121k 500k
Total Assets 89.83M 46.28M 58.24M 72.43M
Common Stock 58k 58k 76k 100k
Other Current Assets
Retained Earnings -2.22B -2.28B -2.33B -2.43B
Treasury Stock -10.64M 2k
Cash 36.44M 31.14M 40.39M 65.45M
Total Current Liabilities 23.05M 18.49M 17.04M 66.65M
Other Stockholder Equity -10.64M 2k
Property, Plant, and Equipment 1.79M 4.61M 2.87M 3.29M
Total Current Assets 82.49M 35.58M 54.33M 68.38M
Net Tangible Assets 58.69M 23.69M 40.03M 3.77M
Net Receivables 13.68M
Accounts Payable 4.5M 1.64M 3.89M


Insider Transactions

Here are the insider transactions of stock shares related to CTI BioPharma Corp:

Filer Name Transaction Text Ownership Date Filer Relation Shares
CRAIG ADAM RSale at price 6.00 - 6.04 per share.D2022-11-10Chief Executive Officer242.3k
CRAIG ADAM RConversion of Exercise of derivative security at price 0.84 per share.D2022-11-10Chief Executive Officer242.3k
METZGER MICHAEL ASale at price 5.53 - 5.70 per share.D2022-11-08Director91.5k
METZGER MICHAEL AConversion of Exercise of derivative security at price 0.84 - 1.00 per share.D2022-11-08Director91.5k
KIRSKE DAVID H.Sale at price 6.25 - 6.27 per share.D2022-10-04Chief Financial Officer2.11k
KIRSKE DAVID H.Conversion of Exercise of derivative security at price 0.95 per share.D2022-10-04Chief Financial Officer2.11k
KIRSKE DAVID H.Sale at price 6.00 - 6.25 per share.D2022-10-03Chief Financial Officer141.04k
KIRSKE DAVID H.Conversion of Exercise of derivative security at price 0.95 per share.D2022-10-03Chief Financial Officer141.04k
KIRSKE DAVID H.Sale at price 6.02 per share.D2022-09-16Chief Financial Officer22.59k
KIRSKE DAVID H.Conversion of Exercise of derivative security at price 0.95 per share.D2022-09-16Chief Financial Officer22.59k
CRAIG ADAM RSale at price 6.43 per share.D2022-09-12Chief Executive Officer242.3k
CRAIG ADAM RConversion of Exercise of derivative security at price 0.84 per share.D2022-09-12Chief Executive Officer242.3k
CRAIG ADAM RPurchase at price 5.50 per share.D2022-08-16Chief Executive Officer5k
BVF PARTNERS L.P.Sale at price 6.12 per share.I2022-08-09Beneficial Owner of more than 10% of a Class of Security8.5M
BVF PARTNERS L.P.I2022-08-09Beneficial Owner of more than 10% of a Class of Security8.38M
METZGER MICHAEL ASale at price 6.50 - 6.55 per share.D2022-07-07Director20.12k
CRAIG ADAM RSale at price 6.00 - 6.11 per share.D2022-07-06Chief Executive Officer72.22k
CRAIG ADAM RConversion of Exercise of derivative security at price 0.84 per share.D2022-07-06Chief Executive Officer72.22k
METZGER MICHAEL ASale at price 5.98 - 6.23 per share.D2022-07-05Director91.5k
METZGER MICHAEL AConversion of Exercise of derivative security at price 0.84 per share.D2022-07-05Director91.5k
CRAIG ADAM RStock Award(Grant) at price 5.97 per share.D2022-06-30Chief Executive Officer6.18k
KIRSKE DAVID H.Stock Award(Grant) at price 5.97 per share.D2022-06-30Chief Financial Officer9.52k
KIRSKE DAVID H.Sale at price 6.00 - 6.25 per share.D2022-06-17Chief Financial Officer60k
KIRSKE DAVID H.Conversion of Exercise of derivative security at price 1.00 - 3.30 per share.D2022-06-17Chief Financial Officer60k
KIRSKE DAVID H.Sale at price 5.50 per share.D2022-06-14Chief Financial Officer10k
KIRSKE DAVID H.Conversion of Exercise of derivative security at price 0.95 per share.D2022-06-14Chief Financial Officer10k
CRAIG ADAM RSale at price 6.00 - 6.01 per share.D2022-06-03Chief Executive Officer72.22k
CRAIG ADAM RConversion of Exercise of derivative security at price 0.84 per share.D2022-06-03Chief Executive Officer72.22k
CRAIG ADAM RStock Award(Grant) at price 2.11 per share.D2021-12-31Chief Executive Officer3.18k
KIRSKE DAVID H.Stock Award(Grant) at price 2.11 - 2.12 per share.D2021-12-31Chief Financial Officer3.6k
SEELEY BRUCE JStock Award(Grant) at price 2.11 - 2.12 per share.D2021-12-31Chief Operating Officer6.41k
CRAIG ADAM RPurchase at price 1.52 per share.D2021-12-02Chief Executive Officer3.5k
CRAIG ADAM RStock Award(Grant) at price 2.12 per share.D2021-06-30Chief Executive Officer5k
BVF PARTNERS L.P.Purchase at price 2.50 per share.D2021-04-01Beneficial Owner of more than 10% of a Class of Security2M
ORBIMED ADVISORS, L.L.C.Sale at price 3.50 per share.I2021-01-07Beneficial Owner of more than 10% of a Class of Security2M

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to CTI BioPharma Corp. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on CTI BioPharma Corp

Here is the result of two systematic investment strategies applied to CTI BioPharma Corp. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on CTI BioPharma Corp

The following chart shows the equity curve of the two systematic investment strategies applied to CTI BioPharma Corp:

CTI BioPharma Corp automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 153.23% on the backtest period.

Performance at glance

Performance

153.23 %

Latent gain

2684.29 $

Invested capital

1751.81 $

Annualized return

37.37 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on CTI BioPharma Corp

This is the result of two momentum investment strategies applied to CTI BioPharma Corp. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on CTI BioPharma Corp

The following chart shows all the entries opened by the momentum investment system on CTI BioPharma Corp:

CTI BioPharma Corp momentum entries
  • The first momentum investment strategy would give 97.79% of return on CTI BioPharma Corp. That represents 4888.67$ of latent gain with 4999.09$ of employed capital.
  • The second momentum investment strategy would give 124.41% of return on CTI BioPharma Corp. That represents 3419.88$ of latent gain with 2748.81$ of employed capital.
Performance at glance (1Q Momentum)

Performance

97.79 %

Latent gain

4888.67 $

Invested capital

4999.09 $

Annualized return

64.02 %
Performance at glance (2Q Momentum)

Performance

124.41 %

Latent gain

3419.88 $

Invested capital

2748.81 $

Annualized return

34.37 %

Momentum equity curve on CTI BioPharma Corp

The following chart shows the equity curve of the two momentum strategies applied to CTI BioPharma Corp:

CTI BioPharma Corp momentum equity

Note: the dividends potentially given by CTI BioPharma Corp are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on CTI BioPharma Corp

The following chart shows the employed capital evolution of the two momentum strategies on CTI BioPharma Corp since the beginning:

CTI BioPharma Corp

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on CTI BioPharma Corp

Buy the dip entry openings on CTI BioPharma Corp

CTI BioPharma Corp

The performance achieved by the robo-advisor on CTI BioPharma Corp is 134.45%. That represents 336.0$ of latent gain with 249.9$ of employed capital. The following chart shows CTI BioPharma Corp stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of CTI BioPharma Corp, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

134.45 %

Latent gain

336.0 $

Invested capital

249.9 $

Annualized return

64.02 %

Equity curve of the strategy applied to CTI BioPharma Corp

The following chart shows the result of the investment strategy applied to CTI BioPharma Corp:

CTI BioPharma Corp

Note: the dividends potentially given by CTI BioPharma Corp are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on CTI BioPharma Corp

The following chart shows the employed capital evolution since the beginning of the investment strategy on CTI BioPharma Corp:

CTI BioPharma Corp

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on CTI BioPharma Corp

In this section, I will compare the three previous investment strategies applied to CTI BioPharma Corp.

Equity curve comparison on CTI BioPharma Corp

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

CTI BioPharma Corp investment strategy comparison

Employed capital comparison on CTI BioPharma Corp

CTI BioPharma Corp investment comparison

Performance comparison on CTI BioPharma Corp

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 153.23% 2684.29$ 1751.81$ 37.37%
Momentum 1 quarter 97.79% 4888.67$ 4999.09$ 25.33%
Momentum 2 quarters 124.41% 3419.88$ 2748.81$ 34.37%
Non-directional 134.45% 336.0$ 249.9$ 64.02%
Annualized return comparison

Automatic investment

37.37 %

Momentum 1Q

34.37 %

Momentum 2Q

34.37 %

Non-directional

64.02 %

Correlated stocks

Here are the most positively and negatively correlated stocks with CTI BioPharma Corp:

Positive correlations

Most correlated stocks this year

  • CTI BioPharma Corp

  • Most correlated stocks last 3 months

  • CTI BioPharma Corp
  • FOCUS HOME INT
  • IPSEN
  • AudioEye Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • SYNERTONE

  • Note: The algorithm computes the probability of correlation between CTI BioPharma Corp and the other stocks. There may be false positives or some missing correlated stocks. If the price of CTI BioPharma Corp does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name CTI BioPharma Corp
    Country United States
    City Seattle
    Address 3101 Western Avenue
    Phone 206 282 7100
    Website www.ctibiopharma.com
    FullTime employees 121
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker CTIC
    Market www.nasdaq.com

    CTI BioPharma Corp ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown